This Crypto Is Set to Explode in December

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

W. Cornwell Biography and Net Worth

Director of Viatris

W. Don Cornwell joined the Viatris board of directors after 23 years of service on the Pfizer board, where he most recently chaired the Regulatory and Compliance Committee and was a member of the Governance & Sustainability Committee. He served as chairman and chief executive officer of Granite Broadcasting Corporation from 1988 until his retirement in August 2009 and served as vice chairman until December 2009. He is a director of American International Group Inc., Natura & Co. Holding Inc., and Blue Meridian Partners. He was a director of Avon Products, Inc. before its acquisition by Natura & Co and was a board member for CVS Caremark for more than 10 years, including two years as chair of the Compensation Committee. Cornwell is a trustee of Big Brothers Big Sisters of New York City.

What is W. Don Cornwell's net worth?: The estimated net worth of W. Don Cornwell is at least $56,340.00 as of May 19th, 2021. Mr. Cornwell owns 4,500 shares of Viatris stock worth more than $56,340 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Cornwell may own. Learn More about W. Don Cornwell's net worth.
How do I contact W. Don Cornwell?: The corporate mailing address for Mr. Cornwell and other Viatris executives is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. Viatris can also be reached via phone at (724) 514-1800 and via email at [email protected]. Learn More on W. Don Cornwell's contact information.
Has W. Don Cornwell been buying or selling shares of Viatris?: W. Don Cornwell has not been actively trading shares of Viatris during the last quarter. Most recently, on Tuesday, March 15th, W Don Cornwell bought 2,700 shares of Viatris stock. The stock was acquired at an average cost of $9.90 per share, with a total value of $26,730.00. Learn More on W. Don Cornwell's trading history.
Who are Viatris' active insiders?: Viatris' insider roster includes Paul Campbell (CAO and Corporate Controller), W. Cornwell (Director), Robert Coury (Chairman), Michael Goettler (CEO), James Kilts (Director), JoElleng Lyons Dillon (Director), Rajiv Malik (Director), Brian Roman (Chief Legal Officer), Menassie Taddese (insider), and Pauline van der Meer Morh (Director). Learn More on Viatris' active insiders.
Are insiders buying or selling shares of Viatris?: During the last twelve months, insiders at the sold shares 14 times. They sold a total of 948,038 shares worth more than $11,069,759.37. The most recent insider tranaction occured on November, 11th when insider Paul Campbell sold 26,925 shares worth more than $346,794.00. Insiders at Viatris own 0.1% of the company. Learn More about insider trades at Viatris.
Information on this page was last updated on 11/11/2024.

W. Don Cornwell Insider Trading History at Viatris

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2022	Buy	2,700	$9.90	$26,730.00
5/21/2021	Buy	500	$15.45	$7,725.00
5/19/2021	Buy	1,500	$15.79	$23,685.00	4,500
3/3/2021	Buy	3,000	$13.84	$41,520.00	3,000

W. Don Cornwell Buying and Selling Activity at Viatris

Viatris Company Overview

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Today's Range

Now: $12.52

$12.14

$12.56

50 Day Range

MA: $12.45

$11.39

$13.37

2 Week Range

Now: $12.52

$9.93

$13.62

Volume

56,375,762 shs

Average Volume

8,704,870 shs

Market Capitalization

$14.94 billion

P/E Ratio

N/A

Dividend Yield

3.96%

Beta

0.96

This Crypto Is Set to Explode in December

From Crypto 101 Media | Ad